Literature DB >> 15592302

Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro.

Patrick Bose1, Simon Black, Mamed Kadyrov, Clemens Bartz, Abdul Shlebak, Lesley Regan, Berthold Huppertz.   

Abstract

OBJECTIVE: Lupus anticoagulant poses a significant risk factor for obstetric complications, whereas heparin improves live birth rates in those pregnancies. Pathophysiology of antiphospholipid antibodies on placental function involves coagulopathies and thrombosis but also dysregulated trophoblast turnover. STUDY
DESIGN: With the use of placental explant cultures, we assessed the effect of lupus anticoagulant positive sera (LA + sera) on apoptosis, mitosis, and invasion of trophoblast and determined the role of unfractionated heparin in regulating these functions.
RESULTS: LA + sera were associated with increased placental apoptosis (TUNEL, M30 formation, DNA laddering). LA + sera decreased villous trophoblast proliferation and reduced extravillous trophoblast invasion through matrigel. Heparin attenuated LA + sera-induced apoptosis and facilitated trophoblast invasion.
CONCLUSION: Lupus anticoagulant may impair placentation by increasing apoptosis, attenuating mitosis and reducing invasion of the trophoblast. The direct effects on trophoblast viability by heparin demonstrate an alternative biologic function for this anticoagulant and raise the possibility that anomalous trophoblast development may be therapeutically regulated.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15592302     DOI: 10.1016/j.ajog.2004.05.014

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

Review 1.  Disturbances in placental immunology: ready for therapeutic interventions?

Authors:  Sinuhe Hahn; Anurag Kumar Gupta; Carolyn Troeger; Corinne Rusterholz; Wolfgang Holzgreve
Journal:  Springer Semin Immunopathol       Date:  2006-04-26

2.  Enhancement of trophoblast differentiation and survival by low molecular weight heparin requires heparin-binding EGF-like growth factor.

Authors:  Alan D Bolnick; Jay M Bolnick; Hamid-Reza Kohan-Ghadr; Brian A Kilburn; Omar J Pasalodos; Pankaj K Singhal; Jing Dai; Michael P Diamond; D Randall Armant; Sascha Drewlo
Journal:  Hum Reprod       Date:  2017-06-01       Impact factor: 6.918

3.  Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway.

Authors:  Melissa J Mulla; Jan J Brosens; Larry W Chamley; Ian Giles; Charis Pericleous; Anisur Rahman; Shawna K Joyce; Britta Panda; Michael J Paidas; Vikki M Abrahams
Journal:  Am J Reprod Immunol       Date:  2009-08       Impact factor: 3.886

Review 4.  Updating on the pathogenic mechanisms 5 of the antiphospholipid antibodies-associated pregnancy loss.

Authors:  Pier Luigi Meroni; Maria Gerosa; Elena Raschi; Silvia Scurati; Claudia Grossi; Maria O Borghi
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 5.  Obstetric Anti-phospholipid Syndrome: State of the Art.

Authors:  Maria Chiara Gerardi; Melissa Alexandre Fernandes; Angela Tincani; Laura Andreoli
Journal:  Curr Rheumatol Rep       Date:  2018-08-13       Impact factor: 4.592

Review 6.  Emerging and Novel Functions of Complement Protein C1q.

Authors:  Lubna Kouser; Shanmuga Priyaa Madhukaran; Abhishek Shastri; Anuvinder Saraon; Janez Ferluga; Maha Al-Mozaini; Uday Kishore
Journal:  Front Immunol       Date:  2015-06-29       Impact factor: 7.561

7.  Purified IgG from patients with obstetric but not IgG from non-obstetric antiphospholipid syndrome inhibit trophoblast invasion.

Authors:  Katie Poulton; Vera M Ripoll; Charis Pericleous; Pier Luigi Meroni; Maria Gerosa; Yiannis Ioannou; Anisur Rahman; Ian P Giles
Journal:  Am J Reprod Immunol       Date:  2014-12-02       Impact factor: 3.886

8.  Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history - an open-label randomised trial (the EPPI trial): study protocol.

Authors:  K M Groom; L M McCowan; P R Stone; L C Chamley; C McLintock
Journal:  BMC Pregnancy Childbirth       Date:  2016-11-22       Impact factor: 3.007

9.  Minimally invasive spinal anesthesia for cesarean section in maternal anticoagulation therapy: a randomized controlled trial.

Authors:  Dan Huang; Linjie Zhu; Jie Chen; Jie Zhou
Journal:  BMC Anesthesiol       Date:  2019-01-12       Impact factor: 2.217

Review 10.  Role of anti-beta2 glycoprotein I antibodies in antiphospholipid syndrome: in vitro and in vivo studies.

Authors:  Pier Luigi Meroni; Nicoletta Ronda; Valentina De Angelis; Claudia Grossi; Elena Raschi; Maria Orietta Borghi
Journal:  Clin Rev Allergy Immunol       Date:  2007-02       Impact factor: 10.817

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.